News and Updates

What is the pipeline? Every new medical device, therapy, treatment, and drug—including those for type 1 diabetes (T1D)—goes through the drug development pipeline. Getting a new therapy or device from the earliest stages of research eventually into the hands of people with T1D is a complicated process. Science takes time (from years to decades!), money […]

What’s happening? Today, Bayer shared data from the phase 3 FINE-ONE clinical trial. These results, which were presented at the American Society of Nephrology Kidney Week in Houston, TX, showed that finerenone (Kerendia™/Firialta™) significantly reduces urine albumin-to-creatinine ratio (UACR), a measure of kidney damage, in people with chronic kidney disease (CKD) associated with type 1 […]

What’s happening? Earlier today, Eli Lilly and Company announced that they are launching two new clinical trials for baricitinib in type 1 diabetes (T1D). These phase 3 trials will investigate whether the drug can delay T1D onset or progression and will open for recruitment soon. Read on to learn more about the trials, why this […]

Breakthrough T1D had the pleasure of speaking with Patti Columbe, a participant in Vertex’s pivotal trial for the manufactured islet therapy zimislecel (formerly VX-880). Patti has been living with type 1 diabetes (T1D) for nearly 39 years. This is one of the most exciting T1D trials in terms of getting us closer to cures for […]

Learn about the people making the CATT1 clinical trial happen, the science behind cadisegliatin for type 1 diabetes, and how to get involved.

A new Breakthrough T1D-funded study finds that people with T1D and their caregivers are largely willing to try advanced new T1D therapies.

Breakthrough T1D’s newest publication outlines a roadmap for beta cell replacement therapies for type 1 diabetes.

Hypoimmune (HIP) islets are making insulin, without immunosuppressants, in the first person treated with type 1 diabetes.

Breakthrough T1D was in Chicago, IL for ADA 2025. Here we report on the latest advancements in cures for type 1 diabetes.

Improving Lives Breakthrough T1D’s Improving Lives program focuses on devices, insulins, adjunctive therapies, treatments for complications, and psychosocial interventions to improve the health and quality of life of people living with T1D. Adjunctive therapies and complications There was significant focus on GLP-1 receptor agonists (GLP-1RAs) and SGLT inhibitors (SGLTi) in reducing long-term complications and improving […]